David Hering, Adagio interim CEO
March 30, 2022 07:45 AM EDT
R&D
Coronavirus

Ada­gio press­es for­ward with their FDA pitch for Covid an­ti­body — de­spite Omi­cron flaws

Jason Mast

Editor

Ada­gio, the Till­man Gern­gross biotech whose $750 mil­lion plan to build a pan-coro­n­avirus an­ti­body seem­ing­ly fell apart in the face of Omi­cron, is back …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

Bris­tol My­ers CEO sig­nals deal­mak­ing will be a top pri­or­i­ty in 2025

Roche CEO warns that tar­iffs could im­pact deal­mak­ing

Roche takes steps to pro­tect it­self from tar­iffs, while Sanofi hangs back

Sanofi's Al­tuvi­i­io clos­ing in on block­buster sta­tus, Dupix­ent sales surge

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times